Fig. 3From: Long-term safety and efficacy of antithymocyte globulin induction: use of integrated national registry data to achieve ten-year follow-up of 10-10 Study participants10-year outcomes according to induction regimen. a Freedom from acute rejection. b Death-censored graft survival. c Patient survival. d All-cause graft survival. Basi, basiliximab; rATG, rabbit antithymocyte globulinBack to article page